[go: up one dir, main page]

US20020110898A1 - Gene repair involving in vivo excision of targeting DNA - Google Patents

Gene repair involving in vivo excision of targeting DNA Download PDF

Info

Publication number
US20020110898A1
US20020110898A1 US09/922,495 US92249501A US2002110898A1 US 20020110898 A1 US20020110898 A1 US 20020110898A1 US 92249501 A US92249501 A US 92249501A US 2002110898 A1 US2002110898 A1 US 2002110898A1
Authority
US
United States
Prior art keywords
dna
vector
restriction endonuclease
targeting
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/922,495
Other languages
English (en)
Inventor
Andre Choulika
Richard Mulligan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur
Boston Childrens Hospital
Original Assignee
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Childrens Hospital filed Critical Boston Childrens Hospital
Priority to US09/922,495 priority Critical patent/US20020110898A1/en
Assigned to INSTITUTE PASTEUR, THE reassignment INSTITUTE PASTEUR, THE ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHOULIKA, ANDRE
Assigned to CHILDREN'S MEDICAL CENTER CORPORATION, THE reassignment CHILDREN'S MEDICAL CENTER CORPORATION, THE ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MULLIGAN, RICHARD C.
Publication of US20020110898A1 publication Critical patent/US20020110898A1/en
Priority to US10/336,069 priority patent/US7285538B2/en
Priority to US11/904,034 priority patent/US7960525B2/en
Priority to US13/101,463 priority patent/US20120165400A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Definitions

  • Homologous recombination and, more specifically D-loop mediated recombination provide a method for genetically modifying chromosomal DNA sequences in a precise way.
  • a methodology for genetically modifying chromosomal DNA sequences in addition to the possibility of introducing small precise mutations in order to alter the activity of the chromosomal DNA sequences, such a methodology makes it possible to correct the genetic defects in genes which can cause disease.
  • current methods for achieving homologous recombination are inherently inefficient, in that homologous recombination or D-loop recombination-mediated gene repair can usually be achieved in only a small proportion of cells that have taken up the relevant “targeting or correcting” DNA.
  • the present invention is related to Applicants' discovery that excision of targeting or correcting DNA from a vector within cells which have taken up the vector significantly increased the frequency of homologous recombination and D-loop recombination-mediated gene repair in these cells.
  • Applicants' invention relates to methods which result in excision of targeting or correcting DNA from a vector within cells which have taken up the vector.
  • the methods comprise introducing into a cell (a) a first vector which comprises a targeting DNA, wherein the targeting DNA comprises DNA homologous to a chromosomal target site and is flanked by specific restriction endonuclease site(s), and (b) a restriction endonuclease which cleaves the restriction endonuclease site(s) and is present in the first vector or a second (separate) vector which comprises a nucleic acid encoding the restriction endonuclease or is introduced as the restriction endonuclease itself.
  • two vectors are introduced into cells: a first vector which comprises a targeting DNA, wherein the targeting DNA comprises DNA homologous to a chromosomal target site and is flanked by specific restriction endonuclease sites and a second vector which comprises a nucleic acid (e.g., DNA) which encodes the restriction endonuclease.
  • a single vector which comprises both targeting DNA wherein the targeting DNA comprises DNA homologous to a chromosomal target site and is flanked by specific restriction endonuclease site(s), and a nucleic acid encoding a restriction endonuclease which cleaves the restriction endonuclease site(s), is introduced into the cell.
  • the targeting DNA is flanked by a restriction endonuclease site if such a site is present at or near either or both ends of the targeting DNA. That is, there can be one restriction endonuclease site present at or near one end of the targeting DNA or there can be two such sites, one at or near each end of the targeting DNA.
  • the restriction endonuclease site(s) are recognized (cleaved) by the restriction endonuclease used in the method. As described below, the endonuclease used in the method is one whose activity does not lead to the death of cells in which it cleaves.
  • One example of an endonuclease useful in the method is a meganuclease enzyme. Two (or more) different restriction endonucleases can be used in the present method.
  • the present invention relates to a method of repairing a specific sequence of interest in chromosomal DNA of a cell comprising introducing into the cell (a) a vector comprising targeting DNA, wherein the targeting DNA is flanked by a restriction endonuclease site or sites and comprises (1) DNA homologous to chromosomal DNA adjacent to the specific sequence of interest and (2) DNA which repairs the specific sequence of interest upon recombination between the targeting DNA and the chromosomal DNA, and (b) a restriction endonuclease which cleaves the restriction endonuclease site(s) present in the vector.
  • the two can be introduced, as described above, in the same or separate vectors or a vector comprising targeting DNA flanked by specific restriction endonuclease site(s) and the endonuclease itself (not in a vector) can be introduced.
  • the targeting DNA is flanked by two restriction endonuclease sites.
  • the targeting DNA is designed such that the homologous DNA is at the left and right arms of the targeting DNA construct and DNA which repairs the specific sequence of interest is inserted between the two arms.
  • the restriction endonuclease is introduced into the cell by introducing into the cell a second vector which comprises a nucleic acid encoding a restriction endonuclease which cleaves the restriction endonuclease site(s) present in the vector.
  • both targeting DNA and nucleic acid encoding the restriction endonuclease which cleaves the specific sites present in the vector are introduced into the cell in the same vector.
  • chromosomal DNA adjacent to a specific sequence of interest refers to chromosomal DNA present near or next to the specific sequence of interest.
  • the specific sequence of interest is a mutation.
  • the present invention also relates to a method of modifying a specific sequence (or gene) in chromosomal DNA of a cell comprising introducing into the cell (a) a vector comprising targeting DNA, wherein the targeting DNA is flanked by a restriction endonuclease site and comprises (1) DNA homologous to the specific sequence (or gene) to be modified and (2) DNA which results in modification of the specific sequence (or gene) upon recombination between the targeting DNA and the chromosomal DNA, and (b) a restriction endonuclease which cleaves the restriction endonuclease site present in the vector.
  • the targeting DNA is flanked by two restriction endonuclease sites (one at or near each end of the targeting DNA).
  • the targeting DNA is designed such that the homologous DNA is at the left and right arms of the targeting DNA construct and DNA which results in modification of the specific sequence (or gene) is inserted between the two arms.
  • the restriction endonuclease is introduced into the cell by introducing into the cell a second vector (either RNA or DNA) which comprises a nucleic acid encoding the restriction endonuclease.
  • both targeting DNA and nucleic acid encoding the restriction endonuclease are introduced into the cell in the same vector.
  • the invention further relates to a method of attenuating an endogenous gene of interest in a cell comprising introducing into the cell (a) a vector comprising targeting DNA, wherein the targeting DNA is flanked by a restriction endonuclease site and comprises (1) DNA homologous to a target site of the endogenous gene of interest and (2) DNA which attenuates the gene of interest upon recombination between the targeting DNA and the gene of interest, and (b) a restriction endonuclease which cleaves the restriction endonuclease site present in the vector.
  • the targeting DNA is flanked by two restriction endonuclease sites.
  • the targeting DNA is designed such that the homologous DNA is at the left and right arms of the targeting DNA construct and DNA which attenuates the gene of interest is located between the two arms.
  • the restriction endonuclease is introduced into the cell by introducing into the cell a second vector (either RNA or DNA) which comprises a nucleic acid encoding the restriction endonuclease.
  • both targeting DNA and nucleic acid encoding the restriction endonuclease are introduced into the cell in the same vector.
  • the present invention also relates to a method of introducing a mutation into a target site of chromosomal DNA of a cell comprising introducing into the cell (a) a first vector comprising targeting DNA, wherein the targeting DNA is flanked by a restriction endonuclease site and comprises (1) DNA homologous to the target site and (2) the mutation to be introduced into the chromosomal DNA, and (b) a second vector (RNA or DNA) comprising a nucleic acid encoding a restriction endonuclease which cleaves the restriction endonuclease site present in the first vector.
  • the targeting DNA is flanked by two restriction endonuclease sites.
  • the targeting DNA is designed such that the homologous DNA is at the left and right arms of the targeting DNA construct and the mutation is located between the two arms.
  • the restriction endonuclease is introduced directly into the cell.
  • both targeting DNA and nucleic acid encoding a restriction endonuclease which cleaves the restriction endonuclease site are introduced into the cell in the same vector.
  • the present invention also relates to the resulting cells and to their uses, such as for production of proteins or other gene products or for treatment or prophylaxis of a condition or disorder in an individual (e.g., a human or other mammal or vertebrate) arising as a result of a genetic defect (mutation).
  • an individual e.g., a human or other mammal or vertebrate
  • a genetic defect e.g., a condition or disorder in an individual (e.g., a human or other mammal or vertebrate) arising as a result of a genetic defect (mutation).
  • cells can be produced (e.g., ex vivo) by the methods described herein and then introduced into an individual using known methods.
  • cells can be modified in the individual (without being removed from the individual).
  • the invention further relates to a method of treating or prophylaxis of a genetic disease in an individual in need thereof.
  • this method comprises introducing into the individual cells which comprise (a) a first vector comprising targeting DNA, wherein the targeting DNA is flanked by a restriction endonuclease site or sites and comprises (1) DNA homologous to chromosomal DNA adjacent to a specific sequence of interest and (2) DNA which repairs the specific sequence of interest upon recombination between the targeting DNA and the chromosomal DNA, and (b) a second vector (RNA or DNA) comprising a nucleic acid encoding a restriction endonuclease which cleaves the restriction endonuclease site(s) present in the first vector.
  • RNA or DNA RNA or DNA
  • this method comprises introducing into the individual cells which comprise (a) a vector comprising targeting DNA, wherein the targeting DNA is flanked by a restriction endonuclease site(s) and comprises (1) DNA homologous to chromosomal DNA and (2) DNA which repairs the specific sequence of interest upon recombination between the targeting DNA and the chromosomal DNA, and (b) a restriction endonuclease which cleaves the restriction endonuclease site present in the vector.
  • this method comprises introducing into the individual cells which comprise a vector comprising (a) targeting DNA, wherein the targeting DNA is flanked by a restriction endonuclease site(s) and comprises (1) DNA homologous to chromosomal DNA and (2) DNA which repairs the specific sequence of interest upon recombination between the targeting DNA and the chromosomal DNA, and (b) nucleic acid encoding a restriction endonuclease which cleaves the restriction endonuclease site present in the plasmid.
  • the targeting DNA is flanked by two restriction endonuclease sites.
  • the targeting DNA is designed such that the homologous DNA is at the left and right arms of the targeting DNA construct and DNA which repairs the specific sequence of interest is located between the two arms.
  • restriction endonucleases and vectors comprising targeting DNA and/or nucleic acid encoding a restriction endonuclease can be administered directly to the individual.
  • FIG. 1 is a schematic diagram of an embodiment of a homologous recombination or D-loop recombination-mediated repair method described herein.
  • FIG. 2 is a table which provides the results from I-SceI induced D-loop recombination-mediated repair experiments in NIH3T3 cells.
  • FIG. 3 is a table providing examples of meganuclease enzymes.
  • the present invention relates to the development of a generally useful method for significantly increasing the frequency of homologous recombination and D-loop recombination-mediated gene repair. At least in vitro, over 1% of a population of transfected cells can be shown to generate the desired recombinational events using the methods described herein. It is likely that these findings represent the ability to achieve homologous recombination and/or gene repair in close to 10% of successfully transfected cells (or higher) when corrected for the efficiency of transfection (the percent cells that take up DNA).
  • the invention relates to the use of methods which lead to the excision of homologous targeting DNA sequences from a recombinant vector within transfected cells (cells which have taken up the vector).
  • the methods comprise introducing into cells (a) a first vector which comprises a targeting DNA, wherein the targeting DNA flanked by specific restriction endonuclease site(s) and comprises DNA homologous to a chromosomal target site, and (b) a restriction endonuclease which cleaves the restriction endonuclease site(s) present in the first vector or a second vector which comprises a nucleic acid encoding the restriction endonuclease.
  • a vector which comprises both targeting DNA and a nucleic acid encoding a restriction endonuclease which cleaves the restriction endonuclease site(s) is introduced into the cell.
  • Nucleic acid encoding the restriction endonuclease is also referred to herein as an expression cassette encoding the restriction endonuclease.
  • Targeting DNA is also referred to herein as a repair matrix and correcting DNA.
  • the targeting DNA is flanked by a restriction endonuclease site if such a site is present at or near either or both ends of the targeting DNA. That is, there can be one restriction endonuclease site present at or near one end of the targeting DNA or there can be two such sites, one at or near each end of the targeting DNA.
  • a restriction endonuclease used in the present invention recognizes a target DNA sequence (e.g., a restriction endonuclease site) which would not lead to death of the cells upon cleavage of the DNA sequence by the restriction endonuclease.
  • a meganuclease enzyme which recognizes a very large DNA sequence, is an example of a restriction endonuclease which can be used in the present invention.
  • An example of a meganuclease enzyme is I-SceI which recognizes an 18-bp site (DNA sequence) that does not appear to be represented in murine or human DNA.
  • Other examples of meganuclease enzymes are provided in FIG. 3.
  • a restriction endonuclease used in the present invention has a specificity of at least 6.7 ⁇ 10 ⁇ 10 of cleaving (cutting) frequency.
  • the present invention relates to a method of repairing a specific sequence of interest in chromosomal DNA of a cell comprising introducing into the cell (a) a vector comprising targeting DNA, wherein the targeting DNA is flanked by a restriction endonuclease site or sites and comprises (1) DNA homologous to chromosomal DNA adjacent to the specific sequence of interest and (2) DNA which repairs the specific sequence of interest upon recombination between the targeting DNA and the chromosomal DNA, and (b) a restriction endonuclease which cleaves the restriction endonuclease site(s) present in the vector.
  • the targeting DNA is flanked by two restriction endonuclease sites (one at or near each end of the targeting DNA).
  • the restriction endonuclease is introduced into the cell by introducing into the cell a second vector which comprises a nucleic acid encoding a restriction endonuclease which cleaves the restriction endonuclease site(s) present in the vector.
  • both targeting DNA and nucleic acid encoding the restriction endonuclease are introduced into the cell in the same vector.
  • the targeting DNA is designed such that homologous recombination, and more preferably, D-loop mediated recombination, occurs between the targeting DNA and chromosomal DNA and, upon recombination, repair of the specific sequence of interest occurs.
  • the targeting DNA is designed to include (1) DNA homologous to chromosomal DNA adjacent to the specific sequence of interest, wherein the homologous DNA is sufficient for recombination between the targeting DNA and chromosomal DNA, and (2) DNA which repairs the specific sequence of interest upon recombination between the targeting DNA and chromosomal DNA.
  • the homologous DNA of the targeting DNA construct flanks each end of the DNA which repairs the specific sequence of interest. That is, the homologous DNA is at the left and right arms of the targeting DNA construct and the DNA which repairs the sequence of interest is located between the two arms.
  • the specific sequence of interest is a mutation.
  • the invention relates to a method of repairing a mutation in chromosomal DNA of a cell comprising introducing into the cell (a) a vector comprising targeting DNA wherein the targeting DNA is flanked by a restriction endonuclease site or sites and comprises (1) DNA homologous to chromosomal DNA adjacent to the mutation and (2) DNA which repairs the mutation upon recombination between the targeting DNA and the chromosomal DNA, and (b) a restriction endonuclease which cleaves the restriction endonuclease site(s) present in the vector.
  • the targeting DNA is flanked by two restriction endonuclease sites (one at or near each end of the targeting DNA).
  • the restriction endonuclease is introduced into the cell by introducing into the cell a second vector which comprises a nucleic acid encoding a restriction endonuclease which cleaves the restriction endonuclease site(s) present in the vector.
  • both targeting DNA and nucleic acid encoding the restriction endonuclease are introduced into the cell in the same vector.
  • the targeting DNA is designed such that homologous recombination, and more preferably, D-loop mediated recombination, occurs between the targeting DNA and chromosomal DNA and, upon recombination, repair of the mutation occurs.
  • the targeting DNA is designed to include (1) DNA homologous to chromosomal DNA adjacent to the mutation, wherein the homologous DNA is sufficient for recombination between the targeting DNA and chromosomal DNA, and (2) DNA which repairs the mutation upon recombination between the targeting DNA and chromosomal DNA.
  • the homologous DNA of the targeting DNA construct flanks each end of the DNA which repairs the mutation. That is, the homologous DNA is at the left and right arms of the targeting DNA construct and the DNA which repairs the mutation is located between the two arms.
  • a mutation refers to a nucleotide change, such as a single or multiple nucleotide substitution, deletion or insertion, in a nucleotide sequence.
  • the mutation is a point mutation.
  • Chromosomal DNA which bears a mutation has a nucleic acid sequence that is different in sequence from that of the corresponding wildtype chromosomal DNA.
  • chromosomal DNA adjacent to a specific sequence of interest refers to chromosomal DNA present near or next to the specific sequence of interest.
  • the present invention also relates to a method of modifying a specific sequence (or gene) in chromosomal DNA of a cell comprising introducing into the cell (a) a vector comprising targeting DNA, wherein the targeting DNA is flanked by a restriction endonuclease site and comprises (1) DNA homologous to the specific sequence (or gene) to be modified and (2) DNA which modifies the specific sequence (or gene) upon recombination between the targeting DNA and the chromosomal DNA, and (b) a restriction endonuclease which cleaves the restriction endonuclease site present in the vector.
  • the targeting DNA is flanked by two restriction endonuclease sites.
  • the restriction endonuclease is introduced into the cell by introducing into the cell a second vector (either RNA or DNA) which comprises a nucleic acid encoding the restriction endonuclease.
  • a second vector either RNA or DNA
  • both targeting DNA and nucleic acid encoding the restriction endonuclease are introduced into the cell in the same vector.
  • the targeting DNA is designed such that homologous recombination, and more preferably, D-loop mediated recombination, occurs between the targeting DNA and chromosomal DNA and, upon recombination, modification of the sequence (or gene) occurs.
  • the targeting DNA is designed to include (1) DNA homologous to the specific sequence (or gene) to be modified, wherein the homologous DNA is sufficient for recombination between the targeting DNA and chromosomal DNA, and (2) DNA which modifies the specific sequence (or gene) upon recombination between the targeting DNA and the chromosomal DNA.
  • the homologous DNA of the targeting DNA construct flanks each end of the DNA which modifies the specific sequence (or gene). That is, the homologous DNA is at the left and right arms of the targeting DNA construct and the DNA which modifies the specific sequence (or gene) is located between the two arms.
  • the invention further relates to a method of attenuating or inactivating an endogenous gene of interest in a cell comprising introducing into the cell (a) a vector comprising targeting DNA, wherein the targeting DNA is flanked by a restriction endonuclease site and comprises (1) DNA homologous to a target site of the endogenous gene of interest and (2) DNA which attenuates or inactivates the gene of interest upon recombination between the targeting DNA and the gene of interest, and (b) a restriction endonuclease which cleaves the restriction endonuclease site present in the vector.
  • the targeting DNA is flanked by two restriction endonuclease sites, as described above.
  • the restriction endonuclease is introduced into the cell by introducing into the cell a second vector (either RNA or DNA) which comprises a nucleic acid encoding the restriction endonuclease.
  • a second vector either RNA or DNA
  • both the targeting DNA and the nucleic acid encoding the restriction endonuclease are introduced into the cell in the same vector.
  • the targeting DNA is designed such that homologous recombination, and more preferably, D-loop mediated recombination, occurs between the targeting DNA and endogenous gene of interest and, upon recombination, attenuation or inactivation of the gene of interest occurs.
  • the targeting DNA is designed to include (1) DNA homologous to a target site of the endogenous gene of interest, wherein the homologous DNA is sufficient for recombination between the targeting DNA and the gene of interest, and (2) DNA which attenuates or inactivates the gene of interest upon recombination between the targeting DNA and the gene of interest.
  • the homologous DNA of the targeting DNA construct flanks each end of the DNA which attenuates or inactivates the gene of interest. That is, the homologous DNA is at the left and right arms of the targeting DNA construct and the DNA which attenuates or inactivates the gene of interest is located between the two arms.
  • the present invention also relates to a method of introducing a mutation into a target site (or gene) of chromosomal DNA of a cell comprising introducing into the cell (a) a first vector comprising targeting DNA, wherein the targeting DNA is flanked by a restriction endonuclease site and comprises (1) DNA homologous to the target site (or gene) and (2) the mutation to be introduced into the chromosomal DNA, and (b) a second vector (RNA or DNA) comprising a nucleic acid encoding a restriction endonuclease which cleaves the restriction endonuclease site present in the first vector.
  • the targeting DNA is flanked by two restriction endonuclease sites.
  • the restriction endonuclease is introduced directly into the cell.
  • both targeting DNA and nucleic acid encoding a restriction endonuclease which cleaves the restriction endonuclease site are introduced into the cell in the same vector.
  • the targeting DNA is designed such that homologous recombination, and more preferably, D-loop mediated recombination, occurs between the targeting DNA and the chromosomal DNA and, upon recombination, a mutation is introduced into the target site (or gene).
  • the targeting DNA is designed to include (1) DNA homologous to the target site (or gene), wherein the homologous DNA is sufficient for recombination between the targeting DNA and the chromosomal DNA, and (2) the mutation which is introduced into the chromosomal DNA upon recombination between the targeting DNA and the chromosomal DNA.
  • the homologous DNA of the targeting DNA construct flanks each end of the mutation. That is, the homologous DNA is at the left and right arms of the targeting DNA construct and the mutation to be introduced into the chromosomal DNA (i.e., into a target site or gene) is located between the two arms.
  • the invention further relates to a method of treating or prophylaxis of a genetic disease in an individual in need thereof.
  • a genetic disease refers to a disease or disorder that arises as a result of a genetic defect (mutation) in a gene in the individual.
  • the genetic disease arises as a result of a point mutation in a gene in the individual.
  • the method of treating or prophylaxis of a genetic disease in an individual in need thereof comprises introducing into (administering to) the individual cells which comprise (a) a first vector comprising targeting DNA, wherein the targeting DNA is flanked by a restriction endonuclease site and comprises (1) DNA homologous to chromosomal DNA adjacent to a specific sequence of interest and (2) DNA which repairs the specific sequence of interest upon recombination between the targeting DNA and the chromosomal DNA, and (b) a second vector (RNA or DNA) comprising a nucleic acid encoding a restriction endonuclease which cleaves the restriction endonuclease site present in the first vector.
  • a first vector comprising targeting DNA
  • the targeting DNA is flanked by a restriction endonuclease site and comprises (1) DNA homologous to chromosomal DNA adjacent to a specific sequence of interest and (2) DNA which repairs the specific sequence of interest upon recombination between the targeting DNA and the chromoso
  • the method comprises introducing into the individual cells which comprise (a) a vector comprising targeting DNA, wherein the targeting DNA is flanked by a restriction endonuclease site and comprises (1) DNA homologous to chromosomal DNA adjacent to a specific sequence of interest (2) DNA which repairs the specific sequence of interest upon recombination between the targeting DNA and the chromosomal DNA, and (b) a restriction endonuclease which cleaves the restriction endonuclease site present in the vector.
  • the method comprises introducing into the individual cells which comprise a vector comprising (a) targeting DNA, wherein the targeting DNA is flanked by a restriction endonuclease site and comprises (1) DNA homologous to chromosomal DNA adjacent to a specific sequence of interest and (2) DNA which repairs the specific sequence of interest upon recombination between the targeting DNA and the chromosomal DNA, and (b) nucleic acid encoding a restriction endonuclease which cleaves the restriction endonuclease site present in the plasmid.
  • the targeting DNA is flanked by two restriction endonuclease sites.
  • the homologous DNA of the targeting DNA construct flanks each end of the DNA which repairs the specific sequence of interest. That is, the homologous DNA is at the left and right arms of the targeting DNA construct and the DNA which repairs the sequence of interest is located between the two arms.
  • restriction endonucleases and vectors comprising targeting DNA and/or nucleic acid encoding a restriction endonuclease can be administered directly to the individual.
  • the mode of administration is preferably at the location of the target cells.
  • the method comprises introducing into (administering to) the individual (a) a first vector comprising targeting DNA, wherein the targeting DNA is flanked by a restriction endonuclease site and (1) DNA homologous to chromosomal DNA adjacent to a specific sequence of interest and (2) DNA which repairs the specific sequence of interest upon recombination between the targeting DNA and the chromosomal DNA, and (b) a second vector (RNA or DNA) comprising a nucleic acid encoding a restriction endonuclease which cleaves the restriction endonuclease site present in the first vector.
  • a first vector comprising targeting DNA, wherein the targeting DNA is flanked by a restriction endonuclease site and (1) DNA homologous to chromosomal DNA adjacent to a specific sequence of interest and (2) DNA which repairs the specific sequence of interest upon recombination between the targeting DNA and the chromosomal DNA
  • RNA or DNA comprising a nucleic acid encoding a restriction end
  • the method comprises introducing into the individual (a) a vector comprising targeting DNA, wherein the targeting DNA is flanked by a restriction endonuclease site and (1) DNA homologous to chromosomal DNA adjacent to a specific sequence of interest and (2) DNA which repairs the specific sequence of interest upon recombination between the targeting DNA and the chromosomal DNA, and (b) a restriction endonuclease which cleaves the restriction endonuclease site present in the vector.
  • the method comprises introducing into the individual a vector comprising (a) targeting DNA, wherein the targeting DNA is flanked by a restriction endonuclease site and (1) DNA homologous to chromosomal DNA adjacent to a specific sequence of interest and DNA which repairs the specific sequence of interest upon recombination between the targeting DNA and the chromosomal DNA, and (b) nucleic acid encoding a restriction endonuclease which cleaves the restriction endonuclease site present in the plasmid.
  • the targeting DNA is flanked by two restriction endonuclease sites.
  • the invention also relates to the generation of animal models of disease in which restriction endonuclease sites (e.g., I-SceI target sites) are introduced at the site of the disease gene for evaluation of optimal delivery techniques.
  • restriction endonuclease sites e.g., I-SceI target sites
  • the efficiency of gene modification/repair can be enhanced by the addition expression of other gene products.
  • the restriction endonuclease and other gene products can be directly introduced into a cell in conjunction with the correcting DNA or via RNA expression. The approach is applicable to all organisms.
  • Targeting DNA can be manufactured according to methods generally known in the art.
  • targeting DNA can be manufactured by chemical synthesis or recombinant DNA/RNA technology (see, e.g., Sambrook et al., Eds., Molecular Cloning. A Laboratory Manual, 2nd edition, Cold Spring Harbor University Press, New York (1989); and Ausubel et al., Eds., Current Protocols In Molecular Biology , John Wiley & Sons, New York (1997)).
  • a “target site”, as used herein, refers to a distinct chromosomal location at which a chromosomal DNA sequence is to be modified in a precise way in accordance with the methods described herein.
  • a “vector” includes a nucleic acid vector, e.g., a DNA vector, such as a plasmid, a RNA vector, virus or other suitable replicon (e.g., viral vector).
  • a DNA vector such as a plasmid, a RNA vector, virus or other suitable replicon (e.g., viral vector).
  • Viral vectors include retrovirus, adenovirus, parvovirus (e.g., adeno-associated viruses), coronavirus, negative strand RNA viruses such as orthomyxovirus (e.g., influenza virus), rhabdovirus (e.g., rabies and vesicular stomatitis virus), paramyxovirus (e.g.
  • RNA viruses such as picornavirus and alphavirus
  • double stranded DNA viruses including adenovirus, herpesvirus (e.g., Herpes Simplex virus types 1 and 2, Epstein-Barr virus, cytomegalovirus), and poxvirus (e.g., vaccinia, fowlpox and canarypox).
  • herpesvirus e.g., Herpes Simplex virus types 1 and 2, Epstein-Barr virus, cytomegalovirus
  • poxvirus e.g., vaccinia, fowlpox and canarypox
  • Other viruses include Norwalk virus, togavirus, flavivirus, reoviruses, papovavirus, hepadnavirus, and hepatitis virus, for example.
  • retroviruses examples include: avian leukosis-sarcoma, mammalian C-type, B-type viruses, D-type viruses, HTLV-BLV group, lentivirus, spumavirus (Coffin, J. M., Retroviridae: The viruses and their replication, In Fundamental Virology , Third Edition, B. N. Fields, et al., Eds., Lippincott-Raven Publishers, Philadelphia, 1996).
  • murine leukemia viruses include murine leukemia viruses, murine sarcoma viruses, mouse mammary tumor virus, bovine leukemia virus, feline leukemia virus, feline sarcoma virus, avian leukemia virus, human T-cell leukemia virus, baboon endogenous virus, Gibbon ape leukemia virus, Mason Pfizer monkey virus, simian immunodeficiency virus, simian sarcoma virus, Rous sarcoma virus and lentiviruses.
  • vectors are described, for example, in McVey et al., U.S. Pat. No. 5,801,030, the teachings of which are incorporated herein by reference.
  • a vector comprising a nucleic acid encoding a restriction endonuclease contains all or part of the coding sequence for the restriction endonuclease operably linked to one or more expression control sequences whereby the coding sequence is under the control of transcription signals to permit production or synthesis of the restriction endonuclease.
  • expression control sequences include promoter sequences, enhancers, and transcription binding sites. Selection of the promoter will generally depend upon the desired route for expressing the restriction endonuclease.
  • the elements can be isolated from nature, modified from native sequences or manufactured de novo (e.g., by chemical synthesis or recombinant DNA/RNA technology, according to methods known in the art (see, e.g., Sambrook et al., Eds., Molecular Cloning: A Laboratory Manual, 2nd edition, Cold Spring Harbor University Press, New York (1989); and Ausubel et al., Eds., Current Protocols In Molecular Biology , John Wiley & Sons, New York (1997)).
  • the elements can then be isolated and fused together by methods known in the art, such as exploiting and manufacturing compatible cloning or restriction sites.
  • a vector comprising targeting DNA flanked by a restriction endonuclease site can be manufactured according to methods generally known in the art.
  • the vector comprising targeting DNA flanked by a restriction endonuclease site can be manufactured by chemical synthesis or recombinant DNA/RNA technology (see, e.g., Sambrook et al., Eds., Molecular Cloning, A Laboratory Manual, 2nd edition, Cold Spring Harbor University Press, New York, 1989; and Ausubel et al., Eds., Current Protocols In Molecular Biology , John Wiley & Sons, New York, 1994-1997).
  • Vectors comprising targeting DNA flanked by a restriction endonuclease site and/or nucleic acid encoding a restriction endonuclease can be introduced into a cell by a variety of methods (e.g., transformation, transfection, direct uptake, projectile bombardment, using liposomes).
  • suitable methods of transfecting or transforming cells include calcium phosphate precipitation, electroporation, microinjection, infection, lipofection and direct uptake.
  • a vector comprising targeting DNA flanked by a restriction endonuclease site and/or nucleic acid encoding a restriction endonuclease can also be introduced into a cell by targeting the vector to cell membrane phospholipids.
  • targeting of a vector of the present invention can be accomplished by linking the vector molecule to a VSV-G protein, a viral protein with affinity for all cell membrane phospholipids.
  • VSV-G protein a viral protein with affinity for all cell membrane phospholipids.
  • Restriction endonucleases can be introduced into a cell according to methods generally known in the art which are appropriate for the particular restriction endonuclease and cell type.
  • a restriction endonuclease can be introduced into a cell by direct uptake, microinjection, calcium phosphate precipitation, electroporation, infection, and lipofection.
  • Such methods are described in more detail, for example, in Sambrook et al., Molecular Cloning: A Laboratory Manual , Second Edition, Cold Spring Harbor University Press, New York (1989); and Ausubel, et al., Current Protocols in Molecular Biology , John Wiley & Sons, New York (1998). Other suitable methods are also described in the art.
  • the restriction endonuclease can be coupled to a facilitator of protein entry to facilitate introduction of the enzyme into a cell.
  • facilitators of protein entry include tat, HSV VP22 and anthrax toxin. Coupling of a protein to a facilitator of protein entry can be accomplished using methods well known to those practiced in the art. Protein delivery strategies (e.g., HSV VP22, anthrax toxin) can be evaluated in accordance with the methods of the invention described herein.
  • the restriction endonuclease and the vector comprising targeting DNA flanked by a restriction endonuclease site and/or nucleic acid encoding a restriction endonuclease are imported or translocated by the cell from the cytoplasm to the site of action in the nucleus.
  • a cell refers to a prokaryotic cell, such as a bacterial cell, or eukaryotic cell, such as an animal, plant or yeast cell.
  • a cell which is of animal or plant origin can be a stem cell or somatic cell.
  • Suitable animal cells can be of, for example, mammalian, avian or invertebrate origin. Examples of mammalian cells include human (such as HeLa cells), bovine, ovine, porcine, murine (such as embryonic stem cells), rabbit and monkey (such as COS1 cells) cells.
  • the cell may be an embryonic cell, bone marrow stem cell or other progenitor cell.
  • the cell can be, for example, an epithelial cell, fibroblast, smooth muscle cell, blood cell (including a hematopoietic cell, red blood cell, T-cell, B-cell, etc.), tumor cell, cardiac muscle cell, macrophage, dendritic cell, neuronal cell (e.g., a glial cell or astrocyte), or pathogen-infected cell (e.g., those infected by bacteria, viruses, virusoids, parasites, or prions).
  • an epithelial cell including a hematopoietic cell, red blood cell, T-cell, B-cell, etc.
  • tumor cell e.g., a glial cell or astrocyte
  • neuronal cell e.g., a glial cell or astrocyte
  • pathogen-infected cell e.g., those infected by bacteria, viruses, virusoids, parasites, or prions.
  • the cells can be obtained commercially or from a depository or obtained directly from an individual, such as by biopsy.
  • the cells used can be obtained from an individual to whom they will be returned or from another/different individual of the same or different species.
  • nonhuman cells such as pig cells
  • ex vivo treatment is sometimes referred to as ex vivo treatment.
  • Ex vivo therapy has been described, for example, in Kasid et al., Proc. Natl. Acad. Sci. USA, 87:473 (1990); Rosenberg et al., N. Engl. J.
  • the cells need not be isolated from the individual where, for example, it is desirable to deliver the vector to the individual in gene therapy.
  • the term “individual” includes mammals, as well as other animals (e.g., birds, fish, reptiles, insects).
  • mammals e.g., birds, fish, reptiles, insects.
  • Examples of mammalian species include humans and other primates (e.g., monkeys, chimpanzees), rodents (e.g., rats, mice, guinea pigs) and ruminents (e.g., cows, pigs, horses).
  • Restriction endonucleases and vectors which comprise targeting DNA flanked by a restriction endonuclease site and/or nucleic acid encoding a restriction endonuclease can be introduced into an individual using routes of administration generally known in the art (e.g., parenteral, mucosal, nasal, injection, systemic, implant, intraperitoneal, oral, intradermal, transdermal (e.g., in slow release polymers), intramuscular, intravenous including infusion and/or bolus injection, subcutaneous, topical, epidural, buccal, rectal, vaginal, etc.).
  • routes of administration generally known in the art (e.g., parenteral, mucosal, nasal, injection, systemic, implant, intraperitoneal, oral, intradermal, transdermal (e.g., in slow release polymers), intramuscular, intravenous including infusion and/or bolus injection, subcutaneous, topical, epidural, buccal, rectal, vaginal
  • restriction endonucleases and vectors can, preferably, be administered in a pharmaceutically acceptable carrier, such as saline, sterile water, Ringer's solution, and isotonic sodium chloride solution.
  • a pharmaceutically acceptable carrier such as saline, sterile water, Ringer's solution, and isotonic sodium chloride solution.
  • the mode of administration is preferably at the location of the target cells.
  • restriction endonuclease or vector of the present invention administered to an individual will vary depending upon a variety of factors, including mode and route of administration; size, age, sex, health, body weight and diet of the recipient; nature and extent of symptoms of the disease or disorder being treated; kind of concurrent treatment, frequency of treatment, and the effect desired.
  • the p2Wlac plasmid was constructed as follows: First, the pPytknlslacZ plasmid (Henry et al., C. R. Acad. Sci. III, 322(12):1061-1070 (1999)) was digested with the SpeI and HindIII restriction enzymes, resulting in excision from the plasmid of a 578 bp fragment containing the ATG start codon and 178 bp at the 5′ end of the coding region of the nlslacZ gene.
  • the oligonucleotide 5′-CTAGATGCATAGGGATAACAGGGTAAT-3′ (SEQ ID NO:1), paired with 5′-AGCTATTACCCTGTTATCCCTATGCAT-3′ (SEQ ID NO:2), was inserted into the SpeI-Hind III restriction sites of the pPytknlslacZ plasmid (Henry et al., C. R. Acad. Sci. III, 322(12):1061-1070 (1999)) to produce the pWnlslacZ plasmid.
  • Insertion of the oligonucleotide at the SpeI-Hind III restriction sites resulted in destruction of the SpeI and HindIII restriction sites and insertion of a NsiI restriction site and an I-SceI restriction site.
  • the pWnlslacZ plasmid was then digested with the NheI and BglII restriction enzymes, resulting in excision from the plasmid of a 0.6 kb fragment containing the stop codon and SV40 polyadenylation signal at the 3′ end of the nlslacZ gene.
  • nlslacZ gene expression is inactivated.
  • the pWlac plasmid was constructed as follows: First, the pPytknlslacZ plasmid was digested with the SpeI and HindIII restriction enzymes, resulting in excision from the plasmid of a 578 bp fragment containing the ATG start codon and 178 bp at the 5′ end of the coding region of the nlslacZ gene.
  • the oligonucleotide 5′-CTAGATGCATAGGGATAACAGGGTAAT-3′ (SEQ ID NO:1), paired with 5′-AGCTATTACCCTGTTATCCCTATGCAT-3′ (SEQ ID NO:2), was inserted into the SpeI-HindIII restriction sites of the pPytknlslacZ plasmid to produce the pWnlslacZ plasmid. Insertion at this restriction site resulted in destruction of the SpeI and HindIII restriction sites and the insertion of an NsiI restriction site and an I-SceI restriction site.
  • the pWnlslacZ plasmid was digested with the NheI and BglII restriction enzymes, resulting in excision from the plasmid of the 0.6 kb fragment containing the stop codon and SV40 polyadenylation signal at the 3′ end of the nlslacZ gene.
  • the 5′ extensions of the NheI-BglII restriction sites of the pWnlslacZ plasmid were converted to blunt ends by a filling-in reaction using T4 DNA polymerase. The blunted ends were then ligated together.
  • nlslacZ gene expression is inactivated.
  • the p-lac plasmid was constructed as follows: First, the pPytknlslacZ plasmid was digested with the SpeI and HindIII restriction enzymes, resulting in excision from the plasmid of a 578 bp fragment containing the ATG start codon and 178 bp at the 5′ end of the coding region of the nlslacZ gene. The 5′ extensions of the SpeI-HindIII restriction sites of the pPytknlslacZ plasmid were converted to blunt ends by a filling-in reaction using T4 DNA polymerase. The blunted ends were then ligated together to produce the p-lacZ plasmid.
  • the p-lacZ plasmid was digested with the NheI and BglII restriction enzymes, resulting in excision from the plasmid of the 0.6 kb fragment containing the stop codon and SV40 polyadenylation signal at the 3′ end of the nlslacZ gene.
  • the 5′ extensions of the NheI-BglII restriction sites of the pWnlslacZ plasmid were converted to blunt ends by a filling-in reaction using T4 DNA polymerase. The blunted ends were then ligated together.
  • the 2.8 kb linear fragment of the nlslacZ gene used in the experiments described herein was obtained as follows: The pPytknlslacZ plasmid was digested with NheI and HindIII and a 2.8 kb fragment was purified by agarose gel electrophoresis. This 2.8 kb fragment, referred to herein as the lac fragment, contains a fragment of the nlslacZ gene with the ATG start codon, 178 bp at the 5′ end, stop codon and SV40 polyadenylation signal deleted.
  • the target plasmid pPytknlslacZDBcl was produced by digesting the pPytknlslacZ plasmid with the BclI restriction enzyme after demethylation of the plasmid.
  • the 5′ protruding ends were filled-in by the Klenow fragment of E. coli DNA polymerase I and religated.
  • the result is insertion of a 4 base pair direct repeat in the sequence of the nlslacZ gene resulting in a frame shift of the open reading frame, thereby inactivating expression of the gene.
  • the plasmid does not express the ⁇ -galactosidase protein.
  • the target plasmid pPytknlslacZ ⁇ Bcl was produced by digesting the pPytknlslacZ plasmid with the BclI restriction enzyme after demethylation of the plasmid.
  • the 4 base pair 5′ protruding ends were degraded by T4 DNA polymerase and the resulting blunted ends religated.
  • the result is deletion of 4 base pairs within the sequence of the nlslacZ gene resulting in a frame shift of the open reading frame, thereby inactivating expression of the gene.
  • the plasmid does not the ⁇ -galactosidase protein.
  • nlslacZ DNA was extracted from cells in all 48 cultures of Geneticin resistant clones. Fragments of the nlslacZ gene were amplified by polymerase chain reaction (PCR) as described in BioFeedback in BioTechniques , Hanley & J. P. Merlie, Vol. 10, No. 1, p. 56T (1991). Forty-six (46) of 48 clones were positive for the presence of the nlslacZ gene.
  • PCR polymerase chain reaction
  • RNA encoding the mutated nlslacZ gene was amplified by reverse transcriptase polymerase chain reaction (RT-PCR).
  • RT-PCR reverse transcriptase polymerase chain reaction
  • the oligonucleotide primer 5′-TACACGCGTCGTGATTAGCGCCG-3′ (SEQ ID NO:5) was used for lacZ reverse transcription.
  • PCR was performed as described in BioFeedback in BioTechniques , Hanley & J. P. Merlie, Vol. 10, No. 1, p. 56T (1991). Eleven (11) of 24 clones showed a positive reaction.
  • nlslacZ gene DNA was extracted from cells in all 48 cultures of Geneticin resistant clones. Fragments of the nlslacZ gene were amplified by PCR as described in BioFeedback in BioTechniques , Hanley & J. P. Merlie, Vol. 10, No. 1, p. 56T (1991). Forty-eight (48) of 48 clones were positive for the presence of the nlslacZ gene.
  • Two (2) of 66 clones showed cells expressing ⁇ -galactosidase (ranging between 30 to 80% of the cells). Southern blot analysis of these 2 clones showed that 100% of the cells had their nlslacZ gene with a Bcl I site recovered. The lack of correspondence between the expression of the intact nlslacZ open reading frame and the total repair of the genome is probably the result of transgene variegation.
  • the pPytknlslacZD-Bcl construct is integrated into the genomic DNA of NIH 3T3 cells as described in Example 2. In these cells, the nlslacZDBcl gene is transcribed but ⁇ -galactosidase expression is not detected ( ⁇ -gal 31 cells).
  • ⁇ -gal 31 cells are cotransfected with the p2Wlac plasmid containing two I-SceI sites and an expression vector coding for I-SceI endonuclease.
  • the p2Wlac plasmid is linearized in vivo by the I-SceI endonuclease and correct the DBcl mutation by D-loop recombination. As a result, these cells contain a pPytknlslacZ plasmid that expresses ⁇ -galctosidase ( ⁇ -gal + cells).
  • FIG. 1 A schematic diagram of this experiment is depicted in FIG. 1.

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
US09/922,495 1999-02-03 2001-08-03 Gene repair involving in vivo excision of targeting DNA Abandoned US20020110898A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US09/922,495 US20020110898A1 (en) 1999-02-03 2001-08-03 Gene repair involving in vivo excision of targeting DNA
US10/336,069 US7285538B2 (en) 1999-02-03 2003-01-02 Gene repair involving in vivo excision of targeting DNA
US11/904,034 US7960525B2 (en) 1999-02-03 2007-09-25 Gene repair involving in vivo excision of targeting DNA
US13/101,463 US20120165400A1 (en) 1999-02-03 2011-05-05 Gene repair involving in vivo excision of targeting dna

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11847299P 1999-02-03 1999-02-03
PCT/US2000/002949 WO2000046385A1 (fr) 1999-02-03 2000-02-03 Reparation genetique par excision in vivo d'adn de ciblage
US09/922,495 US20020110898A1 (en) 1999-02-03 2001-08-03 Gene repair involving in vivo excision of targeting DNA

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/002949 Continuation WO2000046385A1 (fr) 1999-02-03 2000-02-03 Reparation genetique par excision in vivo d'adn de ciblage

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/336,069 Continuation US7285538B2 (en) 1999-02-03 2003-01-02 Gene repair involving in vivo excision of targeting DNA

Publications (1)

Publication Number Publication Date
US20020110898A1 true US20020110898A1 (en) 2002-08-15

Family

ID=22378818

Family Applications (4)

Application Number Title Priority Date Filing Date
US09/922,495 Abandoned US20020110898A1 (en) 1999-02-03 2001-08-03 Gene repair involving in vivo excision of targeting DNA
US10/336,069 Expired - Lifetime US7285538B2 (en) 1999-02-03 2003-01-02 Gene repair involving in vivo excision of targeting DNA
US11/904,034 Expired - Fee Related US7960525B2 (en) 1999-02-03 2007-09-25 Gene repair involving in vivo excision of targeting DNA
US13/101,463 Abandoned US20120165400A1 (en) 1999-02-03 2011-05-05 Gene repair involving in vivo excision of targeting dna

Family Applications After (3)

Application Number Title Priority Date Filing Date
US10/336,069 Expired - Lifetime US7285538B2 (en) 1999-02-03 2003-01-02 Gene repair involving in vivo excision of targeting DNA
US11/904,034 Expired - Fee Related US7960525B2 (en) 1999-02-03 2007-09-25 Gene repair involving in vivo excision of targeting DNA
US13/101,463 Abandoned US20120165400A1 (en) 1999-02-03 2011-05-05 Gene repair involving in vivo excision of targeting dna

Country Status (6)

Country Link
US (4) US20020110898A1 (fr)
EP (1) EP1151124A1 (fr)
JP (1) JP2002535994A (fr)
AU (1) AU2982300A (fr)
CA (1) CA2360878A1 (fr)
WO (1) WO2000046385A1 (fr)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232410A1 (en) * 2002-03-21 2003-12-18 Monika Liljedahl Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
US20040019002A1 (en) * 1999-02-03 2004-01-29 The Children's Medical Center Corporation Gene repair involving the induction of double-stranded DNA cleavage at a chromosomal target site
US20050026157A1 (en) * 2002-09-05 2005-02-03 David Baltimore Use of chimeric nucleases to stimulate gene targeting
US20050064474A1 (en) * 2003-08-08 2005-03-24 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US20050208489A1 (en) * 2002-01-23 2005-09-22 Dana Carroll Targeted chromosomal mutagenasis using zinc finger nucleases
US20060188987A1 (en) * 2003-08-08 2006-08-24 Dmitry Guschin Targeted deletion of cellular DNA sequences
US20090060896A1 (en) * 1999-02-03 2009-03-05 The Children's Medical Center Corporation Gene repair involving in vivo excision of targeting DNA
US20100071083A1 (en) * 2008-03-12 2010-03-18 Smith James J Temperature-dependent meganuclease activity
US20110033935A1 (en) * 2007-12-07 2011-02-10 Precision Biosciences, Inc. Rationally-designed meganucleases with recognition sequences found in dnase hypersensitive regions of the human genome
US20110113509A1 (en) * 2008-03-11 2011-05-12 Precision Biosciences, Inc. Rationally-designed meganucleases for maize genome engineering
US20110123509A1 (en) * 2008-04-28 2011-05-26 Derek Jantz Fusion molecules of rationally-designed dna-binding proteins and effector domains
US7972854B2 (en) 2004-02-05 2011-07-05 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US20110202479A1 (en) * 2008-07-14 2011-08-18 Derek Jantz Recognition sequences for i-crei-derived meganucleases and uses thereof
US8021867B2 (en) 2005-10-18 2011-09-20 Duke University Rationally-designed meganucleases with altered sequence specificity and DNA-binding affinity
US9249428B2 (en) 2003-08-08 2016-02-02 Sangamo Biosciences, Inc. Methods and compositions for targeted genomic deletion
US11311574B2 (en) 2003-08-08 2022-04-26 Sangamo Therapeutics, Inc. Methods and compositions for targeted cleavage and recombination

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7102055B1 (en) * 1997-11-18 2006-09-05 Pioneer Hi-Bred International, Inc. Compositions and methods for the targeted insertion of a nucleotide sequence of interest into the genome of a plant
AU757672B2 (en) * 1997-11-18 2003-02-27 Pioneer Hi-Bred International, Inc. A method for directional stable transformation of eukaryotic cells
EP2196217A1 (fr) 2001-09-14 2010-06-16 Cytos Biotechnology AG Emballage de substances immunostimulantes dans des particules similaires aux virus: procédés de production et utilisations
WO2009095742A1 (fr) 2008-01-31 2009-08-06 Cellectis Nouvelle méganucléase à chaîne unique dérivée de l'i-crei et ses utilisations
US8206965B2 (en) 2002-03-15 2012-06-26 Cellectis S.A. Hybrid and single chain meganucleases and use thereof
WO2004067753A2 (fr) 2003-01-28 2004-08-12 Cellectis Utilisation de meganucleases pour induire une recombinaison homologue ex vivo et in toto dans des tissus somatiques de vertebre et application de cette utilisation
PL1907553T3 (pl) * 2005-07-18 2013-02-28 Pioneer Hi Bred Int Zmodyfikowane miejsca rekombinacji FRT oraz sposoby ich zastosowania
US7852247B2 (en) * 2006-12-05 2010-12-14 Texas Instruments Incorporated Mixed-signal filter
US8912392B2 (en) * 2007-06-29 2014-12-16 Pioneer Hi-Bred International, Inc. Methods for altering the genome of a monocot plant cell

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US285538A (en) * 1883-09-25 Ore-crusher
US5436150A (en) 1992-04-03 1995-07-25 The Johns Hopkins University Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
US5792632A (en) * 1992-05-05 1998-08-11 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US5474896A (en) 1992-05-05 1995-12-12 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
ATE178654T1 (de) 1993-12-20 1999-04-15 Akzo Nobel Nv Impstoff zum schutze von pferden gegen pferdeherpesvirus-infektionen
US5830729A (en) * 1996-04-18 1998-11-03 Institut Pasteur I Sce I-induced gene replacement and gene conversion in embryonic stem cells
AU2982900A (en) 1999-02-03 2000-08-25 Children's Medical Center Corporation Gene repair involving the induction of double-stranded dna cleavage at a chromosomal target site
WO2000046385A1 (fr) 1999-02-03 2000-08-10 The Children's Medical Center Corporation Reparation genetique par excision in vivo d'adn de ciblage
ATE466088T1 (de) * 2001-09-14 2010-05-15 Cellectis Zufällige integration von polynukleotide nach in vivo linearisierung
JP3915752B2 (ja) * 2003-07-25 2007-05-16 船井電機株式会社 デジタル情報記録装置およびそれを備える映像記録再生装置

Cited By (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100111924A1 (en) * 1999-02-03 2010-05-06 Institut Pasteur Chromosomal Modification Involving the Induction of Double-Stranded DNA Cleavage and Homologous Recombination at the Cleavage Site
US20040019002A1 (en) * 1999-02-03 2004-01-29 The Children's Medical Center Corporation Gene repair involving the induction of double-stranded DNA cleavage at a chromosomal target site
US7960525B2 (en) 1999-02-03 2011-06-14 The Institute Pasteur Gene repair involving in vivo excision of targeting DNA
US20090060896A1 (en) * 1999-02-03 2009-03-05 The Children's Medical Center Corporation Gene repair involving in vivo excision of targeting DNA
US20070141038A1 (en) * 1999-02-03 2007-06-21 Andre Choulika Gene repair involving the induction of double-stranded DNA cleavage at a chromosomal target site
US7629326B2 (en) 1999-02-03 2009-12-08 Institut Pasteur Chromosomal modification involving the induction of double-stranded DNA cleavage and homologous recombination at the cleavage site
US20050208489A1 (en) * 2002-01-23 2005-09-22 Dana Carroll Targeted chromosomal mutagenasis using zinc finger nucleases
US9145565B2 (en) 2002-01-23 2015-09-29 University Of Utah Research Foundation Targeted chromosomal mutagenesis using zinc finger nucleases
US20110014601A2 (en) * 2002-01-23 2011-01-20 University Of Utah Research Foundation Targeted Chromosomal Mutagenesis Using Zinc Finger Nucleases
US8106255B2 (en) 2002-01-23 2012-01-31 Dana Carroll Targeted chromosomal mutagenasis using zinc finger nucleases
US20080209587A1 (en) * 2002-03-21 2008-08-28 Sangamo Biosciences, Inc. Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
US20090305402A1 (en) * 2002-03-21 2009-12-10 Sangamo Biosciences, Inc. Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
US20030232410A1 (en) * 2002-03-21 2003-12-18 Monika Liljedahl Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
US9447434B2 (en) 2002-09-05 2016-09-20 California Institute Of Technology Use of chimeric nucleases to stimulate gene targeting
US10006053B2 (en) 2002-09-05 2018-06-26 California Institute Of Technology Use of chimeric nucleases to stimulate gene targeting
US20050026157A1 (en) * 2002-09-05 2005-02-03 David Baltimore Use of chimeric nucleases to stimulate gene targeting
US8524500B2 (en) 2003-08-08 2013-09-03 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
US11311574B2 (en) 2003-08-08 2022-04-26 Sangamo Therapeutics, Inc. Methods and compositions for targeted cleavage and recombination
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US10675302B2 (en) 2003-08-08 2020-06-09 Sangamo Therapeutics, Inc. Methods and compositions for targeted cleavage and recombination
US10669557B2 (en) 2003-08-08 2020-06-02 Sangamo Therapeutics, Inc. Targeted deletion of cellular DNA sequences
US20050064474A1 (en) * 2003-08-08 2005-03-24 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US9782437B2 (en) 2003-08-08 2017-10-10 Sangamo Therapeutics, Inc. Methods and compositions for targeted cleavage and recombination
US9752140B2 (en) 2003-08-08 2017-09-05 Sangamo Therapeutics, Inc. Methods and compostions for targeted genomic deletion
US9695442B2 (en) 2003-08-08 2017-07-04 Sangamo Therapeutics, Inc. Targeted deletion of cellular DNA sequences
US20060188987A1 (en) * 2003-08-08 2006-08-24 Dmitry Guschin Targeted deletion of cellular DNA sequences
US9289451B2 (en) 2003-08-08 2016-03-22 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US9249428B2 (en) 2003-08-08 2016-02-02 Sangamo Biosciences, Inc. Methods and compositions for targeted genomic deletion
US20110030076A1 (en) * 2003-08-08 2011-02-03 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US8349810B2 (en) 2004-02-05 2013-01-08 Sangamo Biosciences, Inc. Methods for targeted cleavage and recombination of CCR5
US7972854B2 (en) 2004-02-05 2011-07-05 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US8129134B2 (en) 2005-10-18 2012-03-06 Duke University Methods of cleaving DNA with rationally-designed meganucleases
US8148098B2 (en) 2005-10-18 2012-04-03 Duke University Methods of cleaving DNA with rationally-designed meganucleases
US8021867B2 (en) 2005-10-18 2011-09-20 Duke University Rationally-designed meganucleases with altered sequence specificity and DNA-binding affinity
US8119361B2 (en) 2005-10-18 2012-02-21 Duke University Methods of cleaving DNA with rationally-designed meganucleases
US8377674B2 (en) 2005-10-18 2013-02-19 Duke University Method for producing genetically-modified cells with rationally-designed meganucleases with altered sequence specificity
US8143016B2 (en) 2005-10-18 2012-03-27 Duke University Methods of cleaving DNA with rationally-designed meganucleases
US8143015B2 (en) 2005-10-18 2012-03-27 Duke University Methods of cleaving DNA with rationally-designed meganucleases
US8124369B2 (en) 2005-10-18 2012-02-28 Duke University Method of cleaving DNA with rationally-designed meganucleases
US8133697B2 (en) 2005-10-18 2012-03-13 Duke University Methods of cleaving DNA with rationally-designed meganucleases
US8163514B2 (en) 2005-10-18 2012-04-24 Duke University Methods of cleaving DNA with rationally-designed meganucleases
US8304222B1 (en) 2005-10-18 2012-11-06 Duke University Rationally-designed meganucleases with altered sequence specificity and heterodimer formation
US8119381B2 (en) 2005-10-18 2012-02-21 Duke University Rationally-designed meganucleases with altered sequence specificity and DNA-binding affinity
US20110033935A1 (en) * 2007-12-07 2011-02-10 Precision Biosciences, Inc. Rationally-designed meganucleases with recognition sequences found in dnase hypersensitive regions of the human genome
US20110113509A1 (en) * 2008-03-11 2011-05-12 Precision Biosciences, Inc. Rationally-designed meganucleases for maize genome engineering
US8338157B2 (en) 2008-03-11 2012-12-25 Precision Biosciences, Inc. Rationally-designed meganuclease variants of lig-34 and I-crei for maize genome engineering
US20100071083A1 (en) * 2008-03-12 2010-03-18 Smith James J Temperature-dependent meganuclease activity
US20110123509A1 (en) * 2008-04-28 2011-05-26 Derek Jantz Fusion molecules of rationally-designed dna-binding proteins and effector domains
US9683257B2 (en) 2008-07-14 2017-06-20 Precision Biosciences, Inc. Recognition sequences for I-CreI-derived meganucleases and uses thereof
US20110202479A1 (en) * 2008-07-14 2011-08-18 Derek Jantz Recognition sequences for i-crei-derived meganucleases and uses thereof
US10287626B2 (en) 2008-07-14 2019-05-14 Precision Biosciences, Inc. Recognition sequences for I-CreI-derived meganucleases and uses thereof
US10273524B2 (en) 2008-07-14 2019-04-30 Precision Biosciences, Inc. Recognition sequences for I-CreI-derived meganucleases and uses thereof

Also Published As

Publication number Publication date
US20120165400A1 (en) 2012-06-28
CA2360878A1 (fr) 2000-08-10
US7960525B2 (en) 2011-06-14
US20090060896A1 (en) 2009-03-05
WO2000046385A1 (fr) 2000-08-10
US20030229039A1 (en) 2003-12-11
US7285538B2 (en) 2007-10-23
EP1151124A1 (fr) 2001-11-07
JP2002535994A (ja) 2002-10-29
AU2982300A (en) 2000-08-25

Similar Documents

Publication Publication Date Title
US7960525B2 (en) Gene repair involving in vivo excision of targeting DNA
US7629326B2 (en) Chromosomal modification involving the induction of double-stranded DNA cleavage and homologous recombination at the cleavage site
Danko et al. Direct gene transfer into muscle
CA2497913C (fr) Utilisation de nucleases chimeres pour stimuler le ciblage de genes
US20220290113A1 (en) Programmable dna base editing by nme2cas9-deaminase fusion proteins
TW202028461A (zh) 核酸構築體及使用方法
JP2023525007A (ja) 転位に基づく療法
KR20020057953A (ko) 진핵 세포에서의 서열 특이적 ｄｎａ 재조합
Li et al. Versatile and efficient mammalian genome editing with Type IC CRISPR System of Desulfovibrio vulgaris
AU2004202860B2 (en) Gene repair involving in vivo excision of targeting DNA
US20250002876A1 (en) Mobile elements and chimeric constructs thereof
US20250040522A1 (en) Mutant myocilin disease model and uses thereof
CN114144231A (zh) 用于治疗癌症的crispr方法
KR20240034143A (ko) 신규한 유전체 세이프 하버 및 이의 용도
Grandchamp et al. Hybrid Lentivirus-phiC31-int-NLS Vector Allows Site-Specific Recombination in
WO2005118835A2 (fr) Souches cellulaires et procedes d'evaluation integrant des polynucleotides

Legal Events

Date Code Title Description
AS Assignment

Owner name: CHILDREN'S MEDICAL CENTER CORPORATION, THE, MASSAC

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MULLIGAN, RICHARD C.;REEL/FRAME:012532/0111

Effective date: 20011219

Owner name: INSTITUTE PASTEUR, THE, FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CHOULIKA, ANDRE;REEL/FRAME:012532/0146

Effective date: 20011211

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION